Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (RAPID KOR)

NCT01913535 PHASE2 TERMINATED Results posted

This study is looking at the efficacy, rapidity, safety, and tolerability of two doses of oral CERC-501 for treating patients with treatment resistant depression who are taking an antidepressant that is not working for them.

Details

Lead sponsor	Massachusetts General Hospital
Phase	PHASE2
Status	TERMINATED
Enrolment	8
Start date	Thu Sep 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jan 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Treatment Resistant Depression

Interventions

• CERC-501
• Placebo

Countries

United States